After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...

English teachers might have told students the word "each" is pronoun that gets a singular verb, but that's only part of the ...

Quantum Dot Corporation's (QDC) new western blot detection kits harness the high brightness, extreme stability and multiple colors of the Qdot Secondary Antibody Conjugates to quantitatively ...

German family-owned pharma major Boehringer Ingelheim has licensed antibody-drug conjugates ADC technology from ...

Already hot for years, antibody-drug conjugates (ADCs) continued to hold charm for the industry, sparking a number of sizable ...

The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...

Antibody-drug conjugates (ADCs) represent a promising ... and mAbs can carry only a limited number of payload molecules. Current ADC payloads fall into two categories: tubulin inhibitors and ...

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an ...

The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by ...

Roche Holding AG kicked off the new year (again) with a potential $1 billion deal, including $80 million up front, for exclusive rights to Innovent Biologics Inc.’s IBI-3009, a DLL3-targeting antibody ...